Apnimed, Inc. (APMD)
Company
Apnimed, Inc. (APMD)
Jul 31, 2026
Health
Initial Public Offering / IPOIPO
Prospectus volume (424B4)192 m USD12,000,000 shares · 16 USD/share
We are a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. Our sole clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA).
Chart/Sentiment
Financials
Apnimed, Inc. (APMD)
Source: SEC Company Facts · USD. Some values may be calculated; please verify them against the official SEC filings.







